PP-01 targets CB-1 recovery and dopamine balance, aiming to ease cannabis withdrawal and boost abstinence as a fast-tracked phase 3 trial advances.
Ginger Constantine, MD
Advertisement
Articles by Ginger Constantine, MD
New data in cannabis use disorder show investigational drug PP-01 cuts irritability 42% in trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Psychiatric Times
1
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
2
Preventing Alzheimer Disease After Brain Injury: Targeting TNF With XPro1595
3
When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery
4
Quiet Comfort: New Details on COMP360 Psilocybin Administration Sessions for the Treatment of PTSD
5